Hold Ajanta Pharma; target of Rs 1520: Spa Research

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Spa Research's report on Ajanta Pharma

Ajanta Pharma reported a 10% YoY growth in revenues for the quarter driven by ~80% YoY growth in Asian sales to INR 1610 million. The US sales saw a growth of ~20% YoY during the quarter to INR 710 million. The company believes the severity of the pricing pressure to have reduced substantially in the US. The company maintained its EBITDA margins YoY at 33.6%, with a PAT growth of 3.6% YoY to INR 1475 million.

Outlook

We expect the company's Revenues/EBITDA/PAT to grow at a CAGR of 15.7%/15%/16.2% between FY17-19E to INR 26.8 billion/INR 9.1 billion/INR 6.7 billion respectively. We recommend Hold rating at a Target Price of INR 1520 (6.8% upside) for a period of 12 months at FY19E PE of 20x.For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More